Virtual Event: Psychopharmacology drug discovery in the 21st century

This innovative event showcased the new approach of academic and biotech groups towards target validation, drug discovery and development in neuroscience.

This event was a collaboration between the Psychiatry Consortium and the British Association for Psychopharmacology (BAP).

Watch a recording of each presentation and the panel Q&A.

The Changing Neuroscience Drug Discovery Landscape in the UK

Presented by Dr Laura Ajram from the Psychiatry Consortium and Medicines Discovery Catapult.

Psychiatry Drug Discovery: Searching for the Low Hanging Fruit in Industry and Academia

Presented by Professor John Atack from the University of Cardiff.

Optimising Preclinical Drug Discovery for Motor Neuron Disease – An Academic / Industrial Collaborative Approach

Presented by Dr Richard Mead from the University of Sheffield.

Drug Discovery Targeting Genetic Hits in Psychiatry (CACNA1C)

Presented by Professor Liz Tunbridge from the University of Oxford.

Advancing Therapeutics against Truly Novel Targets for CNS Diseases: From Human Tissue to the Clinic

Presented by Dr Nicola Brice from Cerevance.

What can we Learn from Oncology? Evolving Methods for Ethical and Efficient Evidence Generation for Off-label Medication use in Neurooncology

Presented by Dr Ndaba Mazibuko from Kings College London.

Panel Q&A with all Speakers

Hosted by Dr Wayne Drevets from Janssen, and featuring Professor Bill Deakin from the University of Manchester.